Adenomyosis Medical Services in China

Adenomyosis is a common, benign gynecological disorder characterized by the ectopic presence of endometrial glands and stroma within the myometrium—the muscular layer of the uterus. Unlike endometriosis, which involves endometrial-like tissue outside the uterus, adenomyosis represents an inward invasion, leading to uterine enlargement, diffuse or focal myometrial thickening, and often significant clinical symptoms. The exact pathogenesis remains incompletely understood but is thought to involve abnormal tissue repair following uterine trauma (e.g., childbirth, cesarean delivery, or uterine surgery), hormonal dysregulation—particularly estrogen-dependent proliferation—and possible stem cell migration from the basalis endometrium into the myometrium. Recent evidence also implicates chronic inflammation, immune dysfunction, and aberrant Wnt/β-catenin signaling in disease initiation and progression. Epidemiologically, adenomyosis affects an estimated 20–35% of reproductive-age women, though prevalence rises sharply with age—reaching up to 60–70% in women undergoing hysterectomy for symptomatic indications. It is frequently underdiagnosed due to overlapping symptoms with fibroids or endometriosis and limitations of conventional imaging; definitive diagnosis historically required histopathology post-hysterectomy, though high-resolution transvaginal ultrasound (TVUS) with expert sonographic criteria and MRI now enable non-invasive diagnosis with >90% sensitivity and specificity in specialized centers. Key risk factors include parity (especially vaginal delivery and cesarean section), prior uterine surgery (e.g., myomectomy, D&C), mid-to-late reproductive age (peak incidence 40–50 years), and possibly genetic predisposition. Notably, nulliparity does not exclude adenomyosis, and increasing numbers of cases are being identified in younger, childbearing women—including those with infertility or recurrent implantation failure. Clinically, adenomyosis profoundly impacts quality of life: heavy menstrual bleeding (menorrhagia) leads to iron-deficiency anemia, fatigue, and reduced work productivity; severe dysmenorrhea (often progressive and unresponsive to NSAIDs) disrupts daily functioning and sleep; chronic pelvic pain and deep dyspareunia strain intimate relationships; and infertility or recurrent pregnancy loss contributes to psychological distress, anxiety, and depression. Many patients report diminished sexual health, social withdrawal, and impaired emotional well-being—factors rarely captured in routine clinical assessments but critical to holistic management. Early recognition and individualized, multidisciplinary care—integrating reproductive endocrinology, minimally invasive surgery, pain medicine, and mental health support—are essential to mitigate long-term morbidity and preserve fertility when desired.

Adenomyosis is a common gynecologic condition characterized by the ectopic presence of endometrial glands and stroma within the myometrium, resulting in uterine enlargement, chronic pelvic pain, menorrhagia, dysmenorrhea, and infertility. As a disorder frequently encountered in reproductive medicine departments, its management requires individualized, stage-adapted strategies that balance symptom control, fertility preservation, and long-term quality of life. Treatment selection depends on symptom severity, patient age, reproductive goals, lesion extent (diffuse vs. focal), and comorbidities such as endometriosis or leiomyomas.

Conservative treatment forms the cornerstone for patients desiring future fertility or those with mild-to-moderate symptoms. It emphasizes non-invasive, reversible interventions aimed at suppressing estrogen-driven glandular activity and reducing inflammation. Lifestyle modifications—including regular aerobic exercise, stress reduction techniques (e.g., mindfulness-based stress reduction), and dietary optimization (low-glycemic, anti-inflammatory diets rich in omega-3 fatty acids and antioxidants)—have demonstrated adjunctive benefits in mitigating pain and menstrual irregularity. Pelvic floor physical therapy is strongly recommended for patients with coexisting myofascial dysfunction or hypertonic pelvic floor muscles, which commonly exacerbate dyspareunia and chronic pelvic discomfort. Transcutaneous electrical nerve stimulation (TENS) and acupuncture—particularly when delivered by licensed practitioners with gynecologic specialization—may provide meaningful analgesia and improve menstrual cycle regulation through neuromodulatory and neuroendocrine pathways.

Pharmacologic management targets hormonal modulation and symptomatic relief. First-line agents include combined oral contraceptives (COCs), particularly low-dose monophasic formulations administered continuously (i.e., skipping placebo weeks) to suppress endometrial proliferation and reduce menstrual flow. Progestin-only therapies—such as levonorgestrel-releasing intrauterine systems (LNG-IUS; e.g., Mirena®, Kyleena®)—are highly effective for localized endometrial suppression, with >80% of patients reporting significant reductions in dysmenorrhea and menorrhagia after six months. For patients with contraindications to estrogen or suboptimal response to LNG-IUS, oral progestins (e.g., norethisterone 5 mg daily from day 5–26) or selective progesterone receptor modulators (SPRMs) like ulipristal acetate (though currently restricted in many jurisdictions due to hepatic safety concerns) may be considered under strict monitoring. Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide acetate) induce temporary hypoestrogenism and are reserved for short-term (<6 months) preoperative use or acute symptom exacerbation; add-back therapy (e.g., norethindrone acetate + estradiol) is mandatory to mitigate bone mineral density loss and vasomotor symptoms. Emerging evidence supports the use of aromatase inhibitors (e.g., letrozole) in refractory cases, especially when local estrogen synthesis within adenomyotic tissue contributes to disease persistence.

Surgical intervention is indicated for severe, medically refractory symptoms, large-volume adenomyosis (>12 cm uterine size), or when fertility preservation is no longer desired. Hysterectomy remains the definitive cure but is contraindicated in women pursuing childbearing. Focal adenomyomectomy—performed via laparoscopy, robotic-assisted laparoscopy, or open abdominal approach—requires meticulous ultrasonographic or MRI-guided delineation of lesion margins and layered myometrial resection with tension-free closure. Success hinges on surgeon expertise: recurrence rates range from 15–35% at five years, and postoperative pregnancy rates average 40–60% among carefully selected candidates (age <38, preserved ovarian reserve, no coexisting tubal pathology). Uterine artery embolization (UAE) demonstrates moderate efficacy for pain reduction but carries higher risks of amenorrhea (10–20%) and diminished ovarian reserve, limiting its utility in reproductive-aged patients. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) offers a non-invasive alternative for select patients with well-defined, non-circumferential lesions; however, its impact on subsequent fertility remains incompletely characterized and should be pursued only within multidisciplinary fertility preservation programs.

China’s reproductive medicine centers offer distinct advantages in adenomyosis management. First, integration of traditional Chinese medicine (TCM) with evidence-based Western therapeutics is standardized and rigorously researched—clinical trials from institutions such as Peking University Third Hospital have validated synergistic effects of herbal formulas (e.g., Guizhi Fuling Wan derivatives) in reducing uterine volume and improving endometrial receptivity when combined with LNG-IUS. Second, China leads globally in minimally invasive surgical innovation: high-volume centers routinely perform robotic-assisted adenomyomectomy with real-time intraoperative ultrasound guidance and near-infrared fluorescence imaging to optimize margin assessment and perfusion mapping. Third, national registries (e.g., the China Adenomyosis Registry) enable robust longitudinal outcome tracking, informing personalized prognostication models incorporating MRI texture analysis, serum CA-125 kinetics, and AMH trajectories. Finally, streamlined access to advanced diagnostics—including 3T MRI with diffusion-weighted imaging and dynamic contrast-enhanced sequences—is widely available in tertiary reproductive centers, facilitating precise phenotyping (junctional zone thickness >12 mm, asymmetry, cystic changes) critical for treatment stratification.

Post-treatment recovery necessitates structured, multidisciplinary follow-up. Patients undergoing medical therapy should undergo clinical reassessment every 3 months for the first year, including pelvic examination, transvaginal ultrasound, and symptom scoring (e.g., Visual Analog Scale for pain, Pictorial Blood Loss Assessment Chart). Those who undergo surgery require serial MRI at 6 and 12 months to assess myometrial healing and detect early recurrence. All patients benefit from endometrial receptivity array (ERA) testing prior to embryo transfer if pursuing IVF, given adenomyosis-associated alterations in window-of-implantation timing. Nutritional counseling emphasizing iron repletion (for menorrhagia-related anemia), vitamin D optimization (linked to reduced inflammatory cytokines), and gut microbiome support (via prebiotics/probiotics) is integral. Psychological support—including cognitive behavioral therapy for pain-related catastrophizing—is routinely embedded in care pathways across leading Chinese reproductive centers. Long-term surveillance includes annual pelvic ultrasound and serum CA-125 monitoring, with prompt MRI referral for new-onset symptoms or progressive uterine enlargement. Ultimately, successful management of adenomyosis demands continuity across medical, surgical, and supportive domains—ensuring not only symptom resolution but also sustained reproductive autonomy and holistic well-being.